-Reuters
Gilead’s Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer
The FDA has accepted for review Gilead Sciences Inc’s (NASDAQ:GILD) Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor…